Solara Active Pharma Sciences Share Price
Sector: Biotechnology & Drugs
494.00 +0.35 (0.07%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
487.55
Today’s High
498.50
52 Week Low
366.95
52 Week High
885.95
494.45 +0.60 (0.12%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
486.00
Today’s High
498.40
52 Week Low
366.70
52 Week High
882.80
Key Metrics
- Market Cap (In Cr) 2363.53
- Beta 1.53
- Div. Yield (%) 0
- P/B 2.07
- TTM P/E -
- Sector P/E 27.03
- Open Price 488
- Prev Close 493.65
Solara Active Pharma Sciences Analysis
Price Analysis
-
1 Week-7.43%
-
3 Months-3.52%
-
6 Month-35.77%
-
YTD-27.16%
-
1 Year0.63%
Risk Meter
- 51% Low risk
- 51% Moderate risk
- 51% Balanced Risk
- 51% High risk
- 51% Extreme risk
Solara Active Pharma Sciences News
Hindustan Zinc, IRB Infra, Coforge among 5 stocks to trade ex-dividend today
3 min read . 15 May 2024Stocks to watch: TaMo, Eicher, Brigade, Abbott, Stylam, Mahanagar Gas, ABB
4 min read . 10 May 2024Solara Active Pharma Sciences Q3 FY24 results: loss at ₹275.34Cr, Revenue decreased by 36.99% YoY
1 min read . 17 Feb 2024Solara Active Pharma Sciences Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 1288.92
- Selling/ General/ Admin Expenses Total
- 410.46
- Depreciation/ Amortization
- 102.66
- Other Operating Expenses Total
- 13.88
- Total Operating Expense
- 1676.63
- Operating Income
- -387.71
- Net Income Before Taxes
- -488.42
- Net Income
- -567.39
- Diluted Normalized EPS
- -113.67
- Period
- 2024
- Total Assets
- 2350.96
- Total Liabilities
- 1417.05
- Total Equity
- 933.91
- Tangible Book Valueper Share Common Eq
- 134.72
- Period
- 2024
- Cashfrom Operating Activities
- 108.87
- Cashfrom Investing Activities
- -3.51
- Cashfrom Financing Activities
- -105.65
- Net Changein Cash
- -0.29
- Period
- 2023
- Total Revenue
- 1443.81
- Selling/ General/ Admin Expenses Total
- 401.23
- Depreciation/ Amortization
- 110.54
- Other Operating Expenses Total
- 9.09
- Total Operating Expense
- 1416.22
- Operating Income
- 27.59
- Net Income Before Taxes
- -44.82
- Net Income
- -22.18
- Diluted Normalized EPS
- -5.6
- Period
- 2023
- Total Assets
- 2899.28
- Total Liabilities
- 1399.07
- Total Equity
- 1500.21
- Tangible Book Valueper Share Common Eq
- 276.68
- Period
- 2023
- Cashfrom Operating Activities
- 156.25
- Cashfrom Investing Activities
- -81.14
- Cashfrom Financing Activities
- -112.76
- Net Changein Cash
- -37.65
- Period
- 2022
- Total Revenue
- 1268.34
- Selling/ General/ Admin Expenses Total
- 429.61
- Depreciation/ Amortization
- 111.64
- Other Operating Expenses Total
- 6.39
- Total Operating Expense
- 1297.82
- Operating Income
- -29.48
- Net Income Before Taxes
- -91.1
- Net Income
- -58.15
- Diluted Normalized EPS
- -14.2
- Period
- 2022
- Total Assets
- 2944.96
- Total Liabilities
- 1420.09
- Total Equity
- 1524.87
- Tangible Book Valueper Share Common Eq
- 279.51
- Period
- 2022
- Cashfrom Operating Activities
- -242.03
- Cashfrom Investing Activities
- -242.85
- Cashfrom Financing Activities
- 333.57
- Net Changein Cash
- -151.31
- Period
- 2021
- Total Revenue
- 1616.88
- Selling/ General/ Admin Expenses Total
- 408.62
- Depreciation/ Amortization
- 107.98
- Other Operating Expenses Total
- 6.52
- Total Operating Expense
- 1332.28
- Operating Income
- 284.6
- Net Income Before Taxes
- 221.5
- Net Income
- 221.4
- Diluted Normalized EPS
- 58.92
- Period
- 2021
- Total Assets
- 2613.58
- Total Liabilities
- 1025.06
- Total Equity
- 1588.52
- Tangible Book Valueper Share Common Eq
- 293.26
- Period
- 2021
- Cashfrom Operating Activities
- 155.46
- Cashfrom Investing Activities
- -106.3
- Cashfrom Financing Activities
- 92.49
- Net Changein Cash
- 141.65
- Period
- 2020
- Total Revenue
- 1321.75
- Selling/ General/ Admin Expenses Total
- 376.14
- Depreciation/ Amortization
- 93.37
- Other Operating Expenses Total
- 3.18
- Total Operating Expense
- 1148.57
- Operating Income
- 173.18
- Net Income Before Taxes
- 114.91
- Net Income
- 114.61
- Diluted Normalized EPS
- 39.57
- Period
- 2020
- Total Assets
- 2153.5
- Total Liabilities
- 1067.56
- Total Equity
- 1085.94
- Tangible Book Valueper Share Common Eq
- 215.68
- Period
- 2020
- Cashfrom Operating Activities
- 244.22
- Cashfrom Investing Activities
- -358.81
- Cashfrom Financing Activities
- 94.91
- Net Changein Cash
- -19.68
- Period
- 2019
- Total Revenue
- 1386.68
- Selling/ General/ Admin Expenses Total
- 356.83
- Depreciation/ Amortization
- 83.09
- Other Operating Expenses Total
- 13.96
- Total Operating Expense
- 1236.26
- Operating Income
- 150.42
- Net Income Before Taxes
- 67.69
- Net Income
- 59.53
- Diluted Normalized EPS
- 24.88
- Period
- 2019
- Total Assets
- 1960.05
- Total Liabilities
- 1004.18
- Total Equity
- 955.87
- Tangible Book Valueper Share Common Eq
- 174.43
- Period
- 2019
- Cashfrom Operating Activities
- 162.38
- Cashfrom Investing Activities
- -109.22
- Cashfrom Financing Activities
- -23.38
- Net Changein Cash
- 29.77
- Period
- 2018
- Total Revenue
- 520.97
- Selling/ General/ Admin Expenses Total
- 67.51
- Depreciation/ Amortization
- 33.98
- Other Operating Expenses Total
- 119.15
- Total Operating Expense
- 492.45
- Operating Income
- 28.52
- Net Income Before Taxes
- 5.83
- Net Income
- 0.38
- Diluted Normalized EPS
- 2.44
- Period
- 2018
- Total Assets
- 1826.3
- Total Liabilities
- 1062.32
- Total Equity
- 763.98
- Tangible Book Valueper Share Common Eq
- 121.5
- Period
- 2018
- Cashfrom Operating Activities
- 63.68
- Cashfrom Investing Activities
- -85.47
- Cashfrom Financing Activities
- 67.74
- Net Changein Cash
- 45.95
- Period
- 2024-12-31
- Total Revenue
- 300.31
- Selling/ General/ Admin Expenses Total
- 51.67
- Depreciation/ Amortization
- 24.54
- Other Operating Expenses Total
- 56.1
- Total Operating Expense
- 267.17
- Operating Income
- 33.14
- Net Income Before Taxes
- 8.09
- Net Income
- 8.09
- Diluted Normalized EPS
- 2.03
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 346.95
- Selling/ General/ Admin Expenses Total
- 52.71
- Depreciation/ Amortization
- 25.34
- Other Operating Expenses Total
- 61.04
- Total Operating Expense
- 310.98
- Operating Income
- 35.97
- Net Income Before Taxes
- 8.01
- Net Income
- 8.01
- Diluted Normalized EPS
- 2.22
- Period
- 2024-09-30
- Total Assets
- 2289.78
- Total Liabilities
- 1203.76
- Total Equity
- 1086.02
- Tangible Book Valueper Share Common Eq
- 190.26
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 99.89
- Cashfrom Investing Activities
- -17.72
- Cashfrom Financing Activities
- -84.7
- Net Changein Cash
- -2.53
- Period
- 2024-06-30
- Total Revenue
- 363.49
- Selling/ General/ Admin Expenses Total
- 55.02
- Depreciation/ Amortization
- 25.07
- Other Operating Expenses Total
- 64.98
- Total Operating Expense
- 346.64
- Operating Income
- 16.85
- Net Income Before Taxes
- -13.46
- Net Income
- -13.46
- Diluted Normalized EPS
- -3.5
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 262.64
- Selling/ General/ Admin Expenses Total
- 56.01
- Depreciation/ Amortization
- 25.25
- Other Operating Expenses Total
- 36.89
- Total Operating Expense
- 400.31
- Operating Income
- -137.67
- Net Income Before Taxes
- -166.66
- Net Income
- -255.34
- Diluted Normalized EPS
- -45.04
- Period
- 2024-03-31
- Total Assets
- 2350.96
- Total Liabilities
- 1417.05
- Total Equity
- 933.91
- Tangible Book Valueper Share Common Eq
- 134.72
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 108.87
- Cashfrom Investing Activities
- -3.51
- Cashfrom Financing Activities
- -105.65
- Net Changein Cash
- -0.29
- Period
- 2023-12-31
- Total Revenue
- 248.73
- Selling/ General/ Admin Expenses Total
- 62.64
- Depreciation/ Amortization
- 25.96
- Other Operating Expenses Total
- 132.26
- Total Operating Expense
- 499.15
- Operating Income
- -250.42
- Net Income Before Taxes
- -275.34
- Net Income
- -275.34
- Diluted Normalized EPS
- -54.42
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 425.24
- Selling/ General/ Admin Expenses Total
- 64.12
- Depreciation/ Amortization
- 26.21
- Other Operating Expenses Total
- 85.96
- Total Operating Expense
- 419.04
- Operating Income
- 6.2
- Net Income Before Taxes
- -17.06
- Net Income
- -17.16
- Diluted Normalized EPS
- -3.06
- Period
- 2023-09-30
- Total Assets
- 2875.33
- Total Liabilities
- 1411.6
- Total Equity
- 1463.73
- Tangible Book Valueper Share Common Eq
- 268.7
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 87.17
- Cashfrom Investing Activities
- -12.92
- Cashfrom Financing Activities
- -76.68
- Net Changein Cash
- -2.43
- Period
- 2023-06-30
- Total Revenue
- 352.31
- Selling/ General/ Admin Expenses Total
- 61.15
- Depreciation/ Amortization
- 25.91
- Other Operating Expenses Total
- 80.05
- Total Operating Expense
- 359.1
- Operating Income
- -6.79
- Net Income Before Taxes
- -29.36
- Net Income
- -19.55
- Diluted Normalized EPS
- -5.43
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 380.62
- Selling/ General/ Admin Expenses Total
- 60.19
- Depreciation/ Amortization
- 26.45
- Other Operating Expenses Total
- 79.23
- Total Operating Expense
- 358.31
- Operating Income
- 22.31
- Net Income Before Taxes
- 5.03
- Net Income
- 3.76
- Diluted Normalized EPS
- 1.04
- Period
- 2023-03-31
- Total Assets
- 2899.28
- Total Liabilities
- 1399.07
- Total Equity
- 1500.21
- Tangible Book Valueper Share Common Eq
- 300.25
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 156.25
- Cashfrom Investing Activities
- -81.14
- Cashfrom Financing Activities
- -112.76
- Net Changein Cash
- -37.65
- Period
- 2022-12-31
- Total Revenue
- 394.75
- Selling/ General/ Admin Expenses Total
- 58.45
- Depreciation/ Amortization
- 27.98
- Other Operating Expenses Total
- 79.91
- Total Operating Expense
- 377.73
- Operating Income
- 17.02
- Net Income Before Taxes
- 0.55
- Net Income
- 0.45
- Diluted Normalized EPS
- 0.12
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Solara Active Pharma Sciences Technical
Moving Average
SMA
- 5 Day504.97
- 10 Day514.4
- 20 Day513.98
- 50 Day503.01
- 100 Day578.82
- 300 Day650.55
Solara Active Pharma Sciences Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Advanced Enzyme Technologies
- 283
- -3.05
- -1.07
- 571.15
- 257.85
- 3173.45
- Dishman Carbogen Amcis
- 193.05
- 0.3
- 0.16
- 307.8
- 132.75
- 3026.69
- Solara Active Pharma Sciences
- 494
- 0.35
- 0.07
- 885.95
- 366.95
- 2363.53
- Suven Life Sciences
- 122.95
- -4.6
- -3.61
- 169
- 83.27
- 2689.65
- Alembic
- 99.54
- -0.26
- -0.26
- 169
- 85.55
- 2559.85
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Advanced Enzyme Technologies
- 21.84
- 2.36
- 12.28
- 24.59
- Dishman Carbogen Amcis
- -
- 0.54
- -0.61
- -1.54
- Solara Active Pharma Sciences
- -
- 2.07
- -4.69
- -4.49
- Suven Life Sciences
- -
- 9.91
- -52.35
- -787.61
- Alembic
- 9.51
- 1.17
- 13.55
- 71.82
Solara Active Pharma Sciences Shareholding
Shareholding Pattern
*Promoter pledging: 13.14%
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 02-Apr-25
- Others
- 26-Mar-25
- Rights Issue & Others
- 24-Jan-25
- Quarterly Results
- 21-Oct-24
- Quarterly Results
- 22-Jul-24
- Quarterly Results
- 29-May-24
- Audited Results
- 09-May-24
- To consider Fund Raising
- 14-Feb-24
- Quarterly Results
- 14-Nov-23
- Quarterly Results
- 14-Aug-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 22-Apr-25
- 20-Mar-25
- POM
- 20-Sept-24
- 29-Aug-24
- AGM
- 08-Apr-24
- 11-Mar-24
- POM
- 20-Jan-24
- 20-Dec-23
- POM
- 15-Sept-23
- 21-Aug-23
- AGM
- 28-Feb-23
- 27-Jan-23
- POM
- 03-Jun-22
- 02-May-22
- POM
- 25-Aug-21
- 28-Jul-21
- AGM
- 16-Mar-21
- 12-Feb-21
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 06-May-21
- -
- 18-Aug-21
- 3


- Announced on
- Record Date
- Ex-Rights Date
- Ratio
- FV
- Premium
- Description
- 05-Jul-23
- 15-May-24
- 15-May-24
- 1:3
- 10
- 365
- Rights issue of equity shares of Rs. 10/- in the ratio of 1:3 @ premium of Rs. 365/-.